Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Clostridium difficile and Clostridium perfringens research, and Gut microbiota and health.
Diagnosis and Management of Clostridioides difficile in Patients with Inflammatory Bowel Disease
Learning ecosystem-scale dynamics from microbiome data with MDSINE2
Diagnostic Uncertainties and Delayed Treatment Protocols Impact Efficacy of FMT for Clostridioides difficile Infection.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
International consensus statement on microbiome testing in clinical practice
Diet and Microbiome-Directed Therapy 2.0 for IBD
S1241 Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
Fecal bile acid profiles predict recurrence in patients with primary
<i>Clostridioides difficile</i>
infection
Oral microbes effective for prevention of recurrent Clostridium difficile infections
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn’s Disease
Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis
Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis
Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent <i>Clostridioides difficile</i> infection and beyond: the contribution of gut microbial-derived metabolites.
The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications
Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients
Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent <i>Clostridioides difficile</i> infection
Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent <em>C. difficile</em> infections in a multi-center retrospective study
Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation
Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience
Endospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota
Recurrent <i>Clostridium difficile</i> infection associates with distinct bile acid and microbiome profiles